Overview
IRIS Followed by mFOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer
Status:
Suspended
Suspended
Trial end date:
2009-03-01
2009-03-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This randomized phase III study compares safety and efficacy of two sequence arms in advanced colorectal cancer: irinotecan and S-1 (IRIS) followed by oxaliplatin containing regimen (arm A), or l-leucovorin (l-LV), 5-FU and oxaliplatin (mFOLFOX6) followed by irinotecan containing regimen (arm B).Phase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Hokkaido Gastrointestinal Cancer Study GroupCollaborator:
Hokkaido University HospitalTreatments:
Camptothecin
Fluorouracil
Irinotecan
Leucovorin
Levoleucovorin
Oxaliplatin
Criteria
Inclusion Criteria:1. Histological diagnosis of colorectal cancer. 2) Age: 18 - 75 years. 3) No prior
chemotherapy 4) ECOG Performance Status 0 to 2 5) A life expectancy of at least 3 months 6)
Adequate function of major organs (bone marrow, heart, lungs, liver etc.). WBC ≧3,500/mm3
and Neutrophil ≧2,000/mm3. Hb ≧10.0 g/dl. Platelet count ≧100,000/mm3. AST and ALT ≦2.5
times the upper limit of normal (excluding liver metastasis). T-Bil ≦1.5 mg/dl. Creatinine
≦1.5 mg/ dl. 7).Patients must have the ability to understand and the willingness to sign a
written informed contact document.
Exclusion Criteria:
1. Patients receiving blood transfusion, blood derivatives or granulocyte-colony
stimulating factor within 7days prior to entering the study.
2. Patients can not have oral intake
3. Patients receiving Flucytosine treatment
4. Patients with severe pleural effusion or ascites.
5. Patients who have brown brain metastasis
6. Patients with diarrhea 4 or more times per day
7. Patients with active gastrointestinal bleeding.
8. Patients with intestinal obstruction
9. Patients with active infection.
10. Patients with serious pulmonary disease (such as interstitial pneumonia, pulmonary
fibrosis, pulmonary emphysema)
11. Patients with serious complications (such as intestinal paralysis, intestinal
obstruction, interstitial pneumonia or pulmonary fibrosis, uncontrolled diabetes
mellitus, heart failure, renal failure, or hepatic failure).
12. Patients with significant cardiac disease.
13. Patients with active multiple cancer.
14. Patients with neuropathy ≥ grade 2
15. Patients who are pregnant, are of childbearing potential, or breast-feeding.
16. Patients with severe mental disorder.
17. Patients with a history of serious allergic reaction.
18. Judged to be ineligible for this protocol by the investigation.
-